GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (STU:35H) » Definitions » Additional Paid-In Capital

Homology Medicines (STU:35H) Additional Paid-In Capital : €564.04 Mil(As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Homology Medicines Additional Paid-In Capital?


Homology Medicines's quarterly additional paid-in capital increased from Jun. 2023 (€565.32 Mil) to Sep. 2023 (€575.52 Mil) but then stayed the same from Sep. 2023 (€575.52 Mil) to Dec. 2023 (€564.04 Mil).

Homology Medicines's annual additional paid-in capital increased from Dec. 2021 (€525.50 Mil) to Dec. 2022 (€573.49 Mil) but then declined from Dec. 2022 (€573.49 Mil) to Dec. 2023 (€564.04 Mil).


Homology Medicines Additional Paid-In Capital Historical Data

The historical data trend for Homology Medicines's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Additional Paid-In Capital Chart

Homology Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 412.20 431.02 525.50 573.49 564.04

Homology Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 573.49 569.79 565.32 575.52 564.04

Homology Medicines Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Homology Medicines Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Homology Medicines (STU:35H) Business Description

Traded in Other Exchanges
Address
One Patriots Park, Bedford, MA, USA, 01730
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (STU:35H) Headlines

No Headlines